中华皮肤科杂志 ›› 2004, Vol. 37 ›› Issue (9): 522-524.

• 论著 • 上一篇    下一篇

复方硝酸溶液治疗寻常疣多中心、随机开放、平行对照临床试验

王爱平1, 韩钢文1, 王家璧2, 孙建方3, 姜祎群3, 刘跃华2, 朱学骏1   

  1. 1. 北京大学第一医院皮肤性病科, 100034;
    2. 中国医学科学院北京协和医院皮肤性病科;
    3. 中国医学科学院、中国协和医科大学皮肤病研究所
  • 收稿日期:2004-01-07 出版日期:2004-09-15 发布日期:2004-09-15

A Randomized Open Parallel Controlled Multi-center Clinical Trial of Solcoderm in the Treatment of Verruca Vulgaris

WANG Ai-ping1, HAN Gang-wen1, WANG Jia-bi2, SUN Jian-fang3, JIANG Yi-qun3, LIU Yue-hua2, ZHU Xue-jun1   

  1. Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China
  • Received:2004-01-07 Online:2004-09-15 Published:2004-09-15

PDF (PC)

170

赞

摘要： 目的 评价复方硝酸溶液(商品名思可得)治疗寻常疣的疗效和安全性,并与冷冻疗法进行比较。方法 采用多中心、随机开放、平行对照的临床试验。结果 主要疗效靶疣体清除率中思可得组为71.6%,冷冻组为77.5%(P=0.451)。次要疗效其他疣体清除率中思可得组为58.7%,冷冻组为75.3%(P=0.034)。思可得组不良反应发生率为4.1%,冷冻组为1.4%(P>0.05)。结论 思可得治疗寻常疣简便、安全、有效。

关键词: 冷冻疗法, 疣, 随机对照试验

Abstract: Objective To assess the clinical efficacy and safety of Solcoderm in the treatment of verruca vulgaris, and to compare with that of cryosurgery. Methods A randomized open, parallel controlled, multi-center clinical trial was conducted. Results The clearance rate in target warts(primary efficacy) was 71.6% in Solcoderm group, and 77.5% in cryosurgery group(P=0.451); the clearance rate(secondary efficacy)in other warts was 58.7% versus 75.3% respectively(P=0.034). Adverse reaction rate was 4.1% in Solcoderm group and 1.4% in cryosurgery group(P>0.05). Conclusions Solcoderm is a simple, safe, and efficient method for the treatment of verruca vulgaris.

Key words: Cryotherapy, Warts, Randomized controlled trials